Naftidrofuryl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 592697

CAS#: 31329-57-4

Description: Naftidrofuryl is a drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic.


Price and Availability

Size
Price

5mg
USD 340
Size
Price

50mg
USD 1580
Size
Price

Naftidrofuryl purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 592697
Name: Naftidrofuryl
CAS#: 31329-57-4
Chemical Formula: C24H33NO3
Exact Mass: 383.246
Molecular Weight: 383.53
Elemental Analysis: C, 75.16; H, 8.67; N, 3.65; O, 12.51


Synonym: Naftidrofuryl

IUPAC/Chemical Name: 2-Furanpropanoic acid, tetrahydro-alpha-(1-naphthalenylmethyl)-, 2-(diethylamino)ethyl ester

InChi Key: KBAFPSLPKGSANY-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3

SMILES Code: O=C(OCCN(CC)CC)C(CC1=C2C=CC=CC2=CC=C1)CC3OCCC3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev. 2012 Dec 12;12:CD001368. doi: 10.1002/14651858.CD001368.pub4. Review. PubMed PMID: 23235580.

2: Smith FB, Bradbury A, Fowkes G. Intravenous naftidrofuryl for critical limb ischaemia. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD002070. doi: 10.1002/14651858.CD002070.pub2. Review. PubMed PMID: 22786478.

3: Kuznetsov MR, Kosykh IV, Iumin SM, Kunitsyn NV, Kuznetsova VF, Tolstikhin VIu, Magnitskiĭ LA. [Use of naftidrofuryl in angiology]. Angiol Sosud Khir. 2014;20(4):27-35. Review. Russian. PubMed PMID: 25490354.

4: Lu D, Song H, Hao Z, Wu T, McCleery J. Naftidrofuryl for dementia. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD002955. doi: 10.1002/14651858.CD002955.pub4. Review. PubMed PMID: 22161372.

5: Hong H, Mackey WC. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication. Clin Ther. 2014 Aug 1;36(8):1290-301. doi: 10.1016/j.clinthera.2014.06.010. Epub 2014 Jul 8. Review. PubMed PMID: 25012728.

6: Meng Y, Squires H, Stevens JW, Simpson E, Harnan S, Thomas S, Michaels J, Stansby G, O'Donnell ME. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology. 2014 Mar;65(3):190-7. doi: 10.1177/0003319712474335. Epub 2013 Jan 31. PubMed PMID: 23378195.

7: Hao J, Chen B, Yao Y, Hossain M, Nagatomo T, Yao H, Kong L, Sun H. Practical access to four stereoisomers of naftidrofuryl and their binding affinity towards 5-hydroxytryptamine 2A receptor. Bioorg Med Chem Lett. 2012 May 15;22(10):3441-4. doi: 10.1016/j.bmcl.2012.03.093. Epub 2012 Apr 1. PubMed PMID: 22516281.

8: Sabry SM, Belal TS, Barary MH, Ibrahim ME. A validated HPLC method for the simultaneous determination of naftidrofuryl oxalate and its degradation product (metabolite), naftidrofuryl acid: applications to pharmaceutical tablets and biological samples. Drug Test Anal. 2013 Jun;5(6):500-8. doi: 10.1002/dta.421. Epub 2012 Feb 28. PubMed PMID: 22374844.

9: Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012 Dec;99(12):1630-8. doi: 10.1002/bjs.8895. Epub 2012 Oct 3. Review. PubMed PMID: 23034699.

10: Leonardi-Bee J, Steiner T, Bath-Hextall F. Naftidrofuryl for acute stroke. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005478. Review. PubMed PMID: 17443593.

11: Roset PN. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638). Br J Surg. 2013 Dec;100(13):1838. doi: 10.1002/bjs.9357. PubMed PMID: 24227374.

12: Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G. Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638). Br J Surg. 2013 Dec;100(13):1838-9. doi: 10.1002/bjs.9358. PubMed PMID: 24227373.

13: D'Hooge D, Lehert P, Clement DL. Naftidrofuryl in quality of life (NIQOL). A Belgian study. Int Angiol. 2001 Dec;20(4):288-94. PubMed PMID: 11782694.

14: De Backer T, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. BMJ. 2009 Mar 10;338:b603. doi: 10.1136/bmj.b603. Review. PubMed PMID: 19276131; PubMed Central PMCID: PMC2659292.

15: Koller MF, Schmid M, Iten PX, Vonlanthen B, Bär W. Fatal intoxication with naftidrofuryl. Leg Med (Tokyo). 2009 Sep;11(5):229-33. doi: 10.1016/j.legalmed.2009.04.003. Epub 2009 Jun 10. PubMed PMID: 19520596.

16: Young JB, Connolly MJ. Naftidrofuryl treatment for rest cramp. Postgrad Med J. 1993 Aug;69(814):624-6. PubMed PMID: 8234106; PubMed Central PMCID: PMC2399689.

17: Praxilene (naftidrofuryl). Drug Ther Bull. 1972 Nov 24;10(24):93-4. PubMed PMID: 4656482.

18: Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, Thomas S, Michaels J, Stansby G. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess. 2011 Dec;15(40):1-210. doi: 10.3310/hta15400. Review. PubMed PMID: 22142554; PubMed Central PMCID: PMC4781353.

19: Le Meur Y, Moesch C, Rincé M, Aldigier JC, Leroux-Robert C. Potential nephrotoxicity of intravenous infusions of naftidrofuryl oxalate. Nephrol Dial Transplant. 1995;10(9):1751-5. PubMed PMID: 8559500.

20: Möller HJ, Hartmann A, Kessler C, Rainer M, Brown T, Gamand S, Lehert P. Naftidrofuryl in the treatment of vascular dementia. Eur Arch Psychiatry Clin Neurosci. 2001 Dec;251(6):247-54. PubMed PMID: 11881837.